Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Diagnostic & imaging agents · 2024

Iomervu (iomeprol)

The FDA approved Iomervu (iomeprol) on November 27, 2024 For use as a radiographic contrast agent.
Brand name
Iomervu
Generic name
iomeprol
FDA approval date
November 27, 2024
Approved use (FDA wording)
For use as a radiographic contrast agent
Company
Bracco
Application
NDA216016
Dosage form / route
SOLUTION · INTRA-ARTERIAL
Drug class (EPC)
Radiographic Contrast Agent [EPC]
Boxed warning on label
Yes (see the FDA label)
Category on this site
Diagnostic & imaging agents

Indications and usage, from the FDA label

IOMERVU is a radiographic contrast agent indicated for: Intra-arterial Procedures † ( 1.1 ) Cerebral arteriography, includingintra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients Visceral and peripheral arteriography and aortography, including IA-DSA, in adults and pediatric patients Coronary arteriography and cardiac ventriculography in adults Radiographic evaluation of cardiac chambers and related arteries in pediatric patients Intravenous Procedures † ( 1.2 ) Computed tomography (CT) of the head and body in adults and pediatric patients CT angiography of intracranial, visceral, and lower extremity arteries in adults and pediatric patients Coronary CT an…

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.